To appeal a Mounjaro denial, get the written reason and your deadline first. The reason decides the fix. If the plan missed proof of type 2 diabetes or the medicines you've tried, your doctor can send a corrected request. Protect your deadline: file any required appeal with records that answer that exact reason.
The RX Index is the independent GLP-1 decision resource that scores telehealth providers and treatment paths on clinical legitimacy, care quality, transparency, access, and cost, so readers can choose the path that fits their situation.
Your deadline depends on your plan. Most job-based and Marketplace plans give you at least 180 days from the day you got the denial. Medicare drug plans generally give you 65 days from the date on the notice. Medicaid health plans give you 60 days from the date on the notice.
Prescribed Mounjaro for weight loss, without diabetes? That's a different problem with a different fix. Jump to that part.
Below, you'll find what common denial phrases mean, a free letter you can copy, and 10 real rulings that show why reviewers overturned some denials and upheld others.
Jump to: Find my denial reason · Check my deadline · Copy the letter · See the real rulings
Here's the honest part up front: no letter, including ours, can promise approval. Your plan's reviewer decides, using your records. What you control is sending the right fix to the right place before the clock runs out. That's what this page helps you do.
If you might run out of Mounjaro soon, tell your prescriber today. They decide the treatment plan while the paperwork moves.
What does your Mounjaro denial actually say?
A Mounjaro denial can mean a missing form, missing proof of diabetes, a rule about other drugs first, or a plan that excludes the drug entirely. Each one needs a different fix. Find the words on your notice in the table below before you write anything.
A few terms first. Prior authorization (PA) is a permission slip from your insurer: your doctor asks the plan to approve coverage before you fill it. You may still owe a copay or other share of the cost. A formulary is your plan's drug list. Step therapy means the plan wants you to try a cheaper or "preferred" drug first, unless your doctor shows why that's wrong for you.
| What your notice or pharmacy says | What it usually means | Your first move | What answers it | Who has it |
|---|---|---|---|---|
| "Prior authorization required" (at the pharmacy, no letter) | The plan never got a request, or hasn't decided yet | Ask if a PA was received and if a written decision exists | PA status, missing items, reference number | Plan, pharmacy, prescriber |
| "Missing information" | A form, signature, or record didn't arrive | Send exactly what's missing; confirm it arrived | The named form or record | Prescriber's office |
| "Type 2 diabetes not documented" | The plan didn't see proof of the diagnosis | Compare what was sent with the plan's written rule | Dated chart notes and lab results (like an A1C of 6.5% or higher), including older records | Prescriber, past doctors |
| "Renewal criteria not met" | The plan wants proof it's still needed or working | Ask which renewal rule was used | Original diagnosis records plus current results | Prescriber, pharmacy |
| "Step therapy" / "try metformin first" | Your plan wants another drug tried first | Ask about a step-therapy exception | Dates you took the other drug and why you stopped, or why it's wrong for you | Prescriber, pharmacy history |
| "Non-formulary" / "use Ozempic, Trulicity, Victoza, or Rybelsus" | Mounjaro isn't on your plan's covered or preferred list | Ask for a formulary exception | What happened on each listed drug, or your doctor's reason it doesn't fit | Prescriber |
| "Quantity limit" / "dose not covered" | Too many pens, or a dose or form outside the rules | Check the prescription and claim; ask about an exception | Exact dose, quantity, and days' supply | Pharmacy, prescriber |
| "Not covered for this use" / "off-label" | The plan says the prescribed use is outside its covered uses | If you have type 2 diabetes, prove it. If you don't, read this section | Accurate diagnosis records | Prescriber |
| "Excluded benefit" | Your plan's contract leaves this drug out | Ask for the exact clause and whether it was applied correctly | Plan document and clause | Plan administrator; HR for work plans |
If the notice only says "does not meet criteria," ask which criterion. That phrase alone doesn't tell you what proof is missing.
Two limits to keep in mind. Don't assume a corrected request stops your appeal clock, so note your deadline before you start fixing paperwork. And never claim a drug failed, or caused side effects, if it didn't. Reviewers check records.
If you only have a pharmacy rejection
A "not covered" message at the pharmacy counter is often not a formal denial yet. Your prescriber may need to send a prior authorization before there's anything to appeal.
Call the number on your insurance card and ask:
"Has a prior authorization for Mounjaro been received? Has a written decision been made? If something is missing, what exactly is it, and what's my reference number?"
Some plans check your claims history automatically. CVS Caremark's published default criteria can clear that check when the claim includes a type 2 diabetes diagnosis code. Without that code, certain fills under a Caremark-administered benefit within the past 730 days can count: at least a 30-day supply of metformin, another qualifying diabetes drug, or qualifying diabetes supplies. A metformin fill must be at least 10 days before the new claim. That past-fill route excludes the drugs targeted by that policy, insulin pen needles, and insulin syringes (CVS Caremark criteria 5694-D). If your diagnosis is new, or your old prescriptions were paid another way, that check can miss you. Your doctor can then send the required records for a PA review.
If a pharmacy rejection code is what you're looking at, here's what common GLP-1 rejection codes mean.
If you have a written denial or a renewal denial
Save the whole notice, including the pages about appeals. Write down two dates: the date printed on it and the date you got it. Different plans start the clock from different dates.
Then ask the plan one question: is this a first request, a renewal after the old approval ran out, or a cutoff before your current approval ends? That answer changes your options, especially on Medicaid.
Your appeal starts with your plan's notice and the deadlines below. If you also want to compare other treatment paths, the right choice depends on your situation. The RX Index's Find My GLP-1 Path tool asks a few quick questions and shows the GLP-1 paths and providers that fit your goals, budget, insurance, and situation. It's free, takes about 2 minutes, and needs no signup.
How long do you have to appeal a Mounjaro denial?
Your deadline to file is not the same as the time your plan has to decide. Most job-based and Marketplace plans give you at least 180 days after you receive the denial. Medicare drug plans generally give you 65 days from the date on the notice, and Medicaid health plans give you 60 days from that date.
| Your coverage | Time to file the first appeal | How fast the plan must decide | Next level if it says no again |
|---|---|---|---|
| Job-based plan (covered by ERISA, the federal employee-benefits law) | At least 180 days after you receive the denial; your plan may allow more (29 CFR 2560.503-1) | 30 days for a drug you haven't gotten yet (15 days per level if there are two levels); 72 hours if urgent | After required internal appeals, external review if eligible. Federal process: request within 4 months; decision within 45 days, or 72 hours if urgent. Confirm the federal or state process that applies |
| Marketplace or other individual plan subject to ACA appeal protections | At least 180 days after you receive the denial (HealthCare.gov) | 30 days before you get the drug; 60 days after; 72 hours if urgent | After required internal appeals, external review if eligible. Federal process: 4 months to request; 45 days to decide, or 72 hours if urgent. State processes may differ (HealthCare.gov) |
| Non-formulary drug exception under essential-health-benefit rules (generally ACA-compliant individual and small-group coverage) | This is an exception request, not the ordinary first appeal; ask the plan for its process | 72 hours; 24 hours if urgent (45 CFR 156.122) | Independent exception review: 72 hours, or 24 if urgent |
| Medicare drug plan (Part D, or Medicare Advantage with drug coverage) | Generally 65 days from the date on the notice (CMS); see the receipt rule below | 7 days for a benefit appeal; 72 hours if urgent. Payment appeals: 14 days | Independent Review Entity, then a judge hearing ($200 minimum in dispute in 2026) |
| Medicaid health plan (managed care) | 60 days from the date on the notice (42 CFR 438.402) | No more than 30 days; 72 hours if urgent, with permitted extensions | State fair hearing: your state gives you 90 to 120 days from the plan's appeal-resolution notice |
| Medicaid run directly by your state, federal employee plan, TRICARE, VA, or other | Use the date in your notice | Set by that program | Set by that program |
Read your notice next to this table. If the dates differ, ask the plan to confirm the deadline and the rule it used right away. Don't wait for that answer to start your appeal. Don't assume a phone call, a resubmitted form, or a doctor's conversation pauses your deadline.
For federal external review, the four-month date moves to the next working day if it falls on a weekend or federal holiday. State processes can have different rules. The helper below calculates only the confirmed routes it supports.
Medicare fine print: the rule itself says 60 days after you receive the notice, and it assumes you got it 5 days after the date printed on it. That's where the 65 days comes from. If you miss it, you can ask the plan for more time for a good reason, with a written explanation (42 CFR 423.582). That's a request, not a promise.
Find your date
Pick your plan type and appeal step, then enter the date it asks for. The helper shows the standard filing date for a confirmed process and what to ask if you're not sure.
Mounjaro appeal deadline helper
Choose the plan type shown by your plan documents or confirmed by member services. Do not infer it from the insurer or employer. Only a plan, stage, and date with a verified rule produce a date; every other route stays date-free.
This helper runs in your browser. It doesn't save or send anything you enter.
Here's how it works in real life. Say you're 52, your job-based Blue Cross plan confirms ERISA rules apply, and the denial reached you on October 3, 2026. For a first appeal, the helper shows "Standard filing date: April 1, 2027," based on the minimum 180-day window. Your plan may allow longer. If the notice gives an earlier date, ask the plan to explain it and start your appeal promptly.
If you don't know what kind of plan you have
The logo on your card doesn't tell you which rules apply. Many job-based plans are "self-funded," which means your employer pays the claims and the insurer just runs them. That changes who handles outside review.
Call member services and ask, "Which plan issued this decision, is it insured or self-funded, which appeal rules apply, and where do I send an appeal?" For work coverage, your HR or benefits office can answer too.
If waiting could hurt your health
Ask your prescriber whether waiting the normal time could seriously harm your health. If so, they can ask for an urgent (expedited) review. It's for real medical risk, not just a faster answer.
ERISA job-based, Marketplace, Medicare drug plan, and Medicaid health plan appeals have a 72-hour urgent option. Medicaid allows extensions in certain cases. For eligible job-based and Marketplace cases, you can ask for outside review alongside the urgent internal appeal if even that wait could seriously harm your health (45 CFR 147.136). A Medicare drug-list exception has its own clock: 72 hours, or 24 if urgent, counted from when your prescriber's supporting statement arrives (CMS exceptions).
The separate essential-health-benefit drug exception also has a 24-hour urgent route. Under that rule, already taking the non-formulary drug can qualify as an urgent circumstance (45 CFR 156.122).
What proof do plans want for Mounjaro?
These five public plan rules ask for proof of type 2 diabetes. Some also ask about other drugs first, and the listed approval periods are 12 or 36 months. Ask for the exact rule used in your case.
Here's what we found when we read five published plan rules on October 21, 2026. They are examples, not a promise of what your plan covers. Some were written before Mounjaro's current label:
| Plan rule (document, date) | Proof of type 2 diabetes | Try metformin first? | Approval lasts | Renewal | Weight loss alone |
|---|---|---|---|---|---|
| UnitedHealthcare commercial (eff. July 1, 2026) | Records with a lab like A1C 6.5%+ or fasting glucose 126 mg/dL or higher, or records confirming a diagnosis made more than 2 years ago | Not listed in this document | 12 months | Can use claims history or diagnosis codes | Says these drugs aren't FDA-approved for weight loss; weight-loss drugs are usually excluded |
| Cigna employer-plan policy IP0701, selected drug lists (eff. June 15, 2026) | Diagnosis with documentation: chart notes, labs, claims, or prescription receipts | Not listed in this document | 1 year | No separate renewal rule stated | Not covered without type 2 diabetes |
| CVS Caremark default criteria (5694-D, P05-2025) | A1C 6.5%+ or a qualifying glucose lab; claims check described above | Not listed in this document | 36 months | No separate renewal rule stated | Coverage criteria require type 2 diabetes |
| Aetna published non-Medicare bulletin (UDR 05-2024; confirm your plan's version) | Type 2 diabetes | Inadequate response, intolerance, or a reason metformin is unsafe; or combination therapy with A1C 7.5%+ | 36 months under 5468-C; 12 months under 5467-C | At least 3 months at a stable maintenance dose and a drop in A1C since starting | Coverage criteria require type 2 diabetes |
| FEP Blue, federal employees (eff. July 1, 2026) | A lab like A1C 6.5%+ or fasting glucose 126 mg/dL or higher | Not listed in this document | 12 months | Type 2 diabetes; blood sugar improved or stable; no other GLP-1 drug at the same time | Coverage criteria require type 2 diabetes |
Quantity rules show up too. CVS Caremark's published limit is 4 single-dose pens or vials per 21 days, or 1 four-dose KwikPen or multi-dose vial per 21 days (Caremark 4525-H). Aetna's bulletin lists 4 single-dose pens or vials per 21 days, or 12 per 63 days. Those 21-day and 63-day windows allow refill processing for 28-day and 84-day supplies; they aren't dosing instructions. FEP Blue lists 12 units per 84 days. Ask the pharmacy to confirm the unit and form used on your claim.
Your employer or plan can change any of these, and a plan with a big insurer's name can still use different rules. That's why step 2 below asks for the exact rule used in your denial.
How to appeal a Mounjaro denial in 6 steps
Build your appeal around the one rule the plan says you didn't meet. Each step should leave you holding a document, a named person who's doing the next part, or proof the plan received your request.
1. Save the denial and protect your deadline
Keep the full notice. Write the deadline on top, and how the plan wants to receive appeals: fax, mail, portal, or a specific form.
If time is short, ask what is needed for a valid, on-time appeal and when extra records can follow. File that appeal before the deadline. Don't wait for a perfect packet and miss the chance to file.
2. Ask for the exact rule and your records
Ask the plan for the specific rule, criteria, and records it used to deny you. Don't rely on a policy you found online, since your plan may use its own version.
If your job-based plan is covered by ERISA, you can get the documents relevant to your claim free, on request, including a free copy of any internal rule or guideline the plan relied on (U.S. Department of Labor). You can ask like this:
"Please send the specific plan provision, medical criteria, and claim records used for this Mounjaro denial, including the policy name and version."
3. Gather the proof that answers the rule
Your prescriber supplies the medical facts. Your job is to line up the denial, the deadline, and the records so their office answers the right question.
| What to collect | Where it comes from | Who gets it | If you can't find it |
|---|---|---|---|
| The exact denial sentence and case number | The full notice | You | Ask the plan to resend the full notice |
| The rule or clause used | Plan document or criteria | The plan | Ask for it in writing |
| Proof of type 2 diabetes | Dated chart notes and lab results, including the original diagnosis | Your prescriber or past doctors | Ask the office that diagnosed you for old records; never guess a number or code |
| Proof it's working (for renewals) | Before-and-after A1C or blood sugar results, past approval, fill history | Prescriber, pharmacy | Ask the pharmacy for a fill history printout |
| What you've tried before | Drug names, dates, and why each stopped | You, pharmacy, prescriber | Pharmacy records show dates; your doctor documents why |
| Heart history, if any | Records of a past heart attack, stroke, or heart disease | Prescriber | Ask whether it applies (see below) |
| Your prescriber's letter | Signed statement answering the disputed rule | Prescriber | Ask if and when the office can write it |
| Any required plan form | Your notice | You or your representative | Ask the plan which form it needs |
| Proof you sent it | Fax receipt, upload confirmation, certified mail | Whoever sends it | Call to confirm the plan received it |
The prescriber's letter is often called a letter of medical necessity. Lilly publishes a sample letter of medical necessity for prescribers that lists past treatments with dates and reasons for stopping. Use it for the format; your prescriber should use the current label for approved uses, since some of the sample's wording is older. Our guide covers what your clinician's medical-necessity letter should include.
4. Decide: fix it, ask for an exception, or appeal
A missing record may just need a correction. A drug that isn't on the plan's list needs an exception request. A written denial of a complete request needs a formal appeal. Confirm which one you're doing, and who is filing it.
A peer-to-peer is a phone call between your doctor and the plan's reviewing doctor. It can help, but don't assume it counts as your formal appeal or pauses your deadline. Ask the plan, and get the answer in writing.
If someone else files for you, like your doctor's office or a family member, ask whether the plan needs a signed representative form. Medicare has specific rules for this.
5. Send the letter with only the records you actually attach
Use the plan's form if it requires one, and add your letter. Number each attachment and list them in the letter. Keep a full copy of everything you send.
Keep the request about Mounjaro. If your clinician decides on a different medicine instead, that's a new prescription with its own approval, not part of this appeal.
6. Confirm the plan got it, and track the next date
Confirm receipt promptly—right away if your deadline is close or the appeal is urgent. Ask whether they received it, what stage it's in, and when to expect a decision. Write down the name and reference number.
A fax receipt proves you sent it. The plan confirming it proves they have it. Get both.
Your free Mounjaro appeal letter
A patient appeal letter names the decision, asks for a review, and points to the records attached. The medical facts and reasons have to come from your records and your prescriber. Copy the blank below and fill it in on your own device or on paper.
You don't need to enter or upload any health information on this page.
[Date]
To: [Appeals department and address, fax, or portal from your notice]
Re: Request to review Mounjaro coverage denial
Member name: [Name]
Member ID: [ID]
Case or reference number: [From your notice]
Date of the decision: [From your notice]
Prescriber: [Name, phone, fax]
I am requesting [the appeal or review named in my notice] of the decision denying coverage for Mounjaro [strength and form prescribed].
The notice says: "[Copy the exact denial reason]." It cites [the policy or plan rule named, if any].
Please review the following response to that reason:
[Explain the one point you disagree with. Point to the attachment and page that supports it. Use only facts in your records or confirmed by your prescriber.]
I am including:
1. [Attachment name]
2. [Attachment name]
[List only what you are actually attaching, including any required plan form and your prescriber's statement.]
Please confirm you received this appeal and tell me the expected decision date. If anything required is missing, please tell me what it is and how and when to send it. Please send your decision in writing, with the reason and any further review rights and deadlines.
[Your name]
[Phone and email]
[Signature, if required]Add only the paragraph that fits your case
Pick the one that matches your denial, fill in the brackets, and paste it into the letter where it says "Please review." Delete anything you can't back up with a record.
Diagnosis not documented: "Please review [dated records] from [clinician or office], which document my type 2 diabetes diagnosis. The disputed requirement is [criterion from the notice], and the supporting record is [attachment and page]."
Renewal denied: "This request is for continued treatment. Please review my original diagnosis records [attachment], my current results [attachment], and my prescriber's explanation of ongoing need [attachment] under [the renewal rule named in the notice]."
Other drugs required first (step therapy or non-formulary): "For each alternative named in the policy, my prescriber's statement explains [the dates I took it and what happened, or the medical reason it isn't right for me]. See [attachment and page]."
Excluded benefit: "Please identify the exact exclusion clause and explain how it applies to the drug and use prescribed. I am asking you to review how it was applied because [the specific, documented reason]."
Message to send your prescriber's office
A clear, short message tells the office exactly what help you need.
My plan denied Mounjaro. The exact reason is "[reason from the notice]," and my deadline to file is [date]. Can your office check which policy applies and send the records or statement that answer that reason? Please tell me whether your office will file the appeal or send the documents to me. [If attached: I've attached the denial notice.] My current supply runs out on [date, if it applies]; please let me know the treatment plan while this is reviewed.Track it until you hear back
Write these on the notice or in your phone: date on the notice; date you received it; which appeal level; filing deadline; where to send it; who is filing; records still needed; date sent; plan's reference number; expected decision date; next deadline if denied. If you don't know one, the answer is "ask the plan," not a guess.
Want help for other GLP-1s or a more detailed packet? Our GLP-1 appeal letter template covers more denial types and types of coverage.
What if your A1C improved, or you don't have type 2 diabetes?
A1C is a blood test that shows your average blood sugar over the past 3 months; 6.5% or higher is in the diabetes range. Without clear symptoms, a second test is needed to confirm a diagnosis (NIDDK). If you were diagnosed with type 2 diabetes and Mounjaro lowered your A1C, the plan may need both the original diagnosis and your current results. If you never had type 2 diabetes, your request is for an off-label use, and an appeal letter can't change that.
Mounjaro's current FDA label covers two uses: blood sugar control in adults and children 10 and older with type 2 diabetes, and lowering the risk of nonfatal heart attack, nonfatal stroke, and cardiovascular death in adults with type 2 diabetes at high risk for those events (Mounjaro prescribing information, revised August 2026). Weight loss, prediabetes, and PCOS aren't on that list.
Your A1C is lower now because the medicine works
This can become a renewal problem. The plan sees a normal-looking A1C today and asks where the diabetes is.
The fix is showing both pieces: the original diagnosis and today's results. UnitedHealthcare's current rules accept records confirming a type 2 diabetes diagnosis made more than 2 years ago. FEP Blue's renewal rule looks for blood sugar that's improved or stable. Aetna's published UDR 05-2024 bulletin asks for at least 3 months at a stable maintenance dose and a drop in A1C since you started. Those are examples, not national rules, so match your packet to your plan's wording.
Say your chart shows type 2 diabetes from 2021, but the new request only included last month's A1C of 6.1%. Ask the office to send the 2021 diagnosis records, the current note, and a line on why treatment should continue. That doesn't guarantee approval. It does answer the question the plan actually asked.
Never stop or change your medicine to push a lab number up for insurance. Ask your prescriber which records to send instead.
If you have heart disease and type 2 diabetes
Since August 2026, Mounjaro's label also covers lowering the risk of major cardiovascular events in adults with type 2 diabetes who are at high risk. Many plan rules were written before that change.
If your prescriber says this use applies to you, they can include the current label and your heart history in the appeal. It doesn't create coverage for anyone without type 2 diabetes, and it doesn't automatically override your plan's rule. It can strengthen a medical-necessity argument.
For a child with type 2 diabetes
Mounjaro's label includes children 10 and older with type 2 diabetes (added December 2025). A parent or guardian usually files the appeal with the child's care team. Lilly's savings card is only for people 18 and older, so ask the care team about other help with cost.
If you were prescribed Mounjaro for weight loss, prediabetes, or PCOS
When a drug is prescribed for something not on its FDA label, that's called off-label use. The UnitedHealthcare and Cigna policies above do not cover Mounjaro for weight loss alone.
An off-label appeal isn't automatically hopeless. In the five obesity-related New York decisions selected for the table below, reviewers overturned four denials. These decisions date from 2022 and 2023. Zepbound was approved for weight management on November 8, 2023; the 2023 case pages don't give an exact decision date. Today's treatment options and plan rules differ. Your clinician can check whether the product approved for weight fits your needs and your coverage.
Zepbound is the same medicine, tirzepatide, made by Lilly. Its label covers weight reduction in adults with obesity, or overweight plus at least one weight-related condition, and moderate-to-severe obstructive sleep apnea in adults with obesity (Zepbound prescribing information, revised August 2026). Think of it as the same car, registered for a different job. Your clinician would need to write a new prescription, and your plan would review it under its own rules. If your plan excludes all weight-loss drugs, that request may be denied too.
More on this: why Mounjaro isn't FDA-approved for weight loss, whether insurance covers Zepbound for weight loss, and coverage for prediabetes.
If you're an adult with commercial insurance through a job or the Marketplace and you and your clinician land on Zepbound for weight, Ro offers a free coverage check. Its checker covers the Zepbound autoinjector pen, Wegovy pen, and Ozempic; those drugs have different approved uses. If a Ro clinician prescribes treatment through its program, its insurance team handles the prior authorization paperwork. Ro doesn't prescribe Mounjaro.
The Body membership costs $39 for the first month, then $149 month to month, or as low as $74/month on a 12-month plan paid upfront ($888 at once). Medication is billed separately (Ro pricing).
Check your Zepbound coverage with Ro
If your plan says the drug is excluded
An exclusion means your plan's contract leaves this drug or use out. That's different from a missing record, and a doctor's letter alone usually can't beat it.
Ask for the exact clause, then check whether it fits your drug and your use. A plan that excludes "weight-loss drugs" may still cover Mounjaro for type 2 diabetes, so a diabetes denial under a weight-loss exclusion can be a misread worth appealing. For work plans, HR can tell you whether the employer ever makes exceptions. Here's how a plan exclusion differs from a prior authorization denial.
What do real Mounjaro appeal decisions show?
These 10 public Mounjaro decisions show why some denials were overturned and others stood. Reviewers weighed prior treatment, side effects, remaining options, and the reason for requesting Mounjaro.
These come from New York's external appeal database and a Massachusetts Medicaid hearing. An external review means a reviewer outside your plan looks at the denial and makes a decision the plan must follow.
| Year | Plan | Diagnosis | What the plan wanted | Result | What decided it |
|---|---|---|---|---|---|
| 2023 | Aetna PPO (case) | Type 2 diabetes | Use listed drugs instead | Overturned | Records showed Trulicity, Ozempic, Victoza, and metformin didn't work or caused reactions; Mounjaro lowered her A1C |
| 2023 | Oscar EPO (case) | Type 2 diabetes | Try Ozempic, Rybelsus, Victoza, Trulicity first | Overturned | Trulicity and Victoza had failed; he couldn't tolerate Ozempic or metformin; stable on Mounjaro |
| 2023 | Aetna EPO (case) | Type 2 diabetes | Try 3 of 4 listed drugs first | Overturned | Ozempic had failed; stable on Mounjaro with insulin; switching risked complications |
| 2023 | Healthfirst HMO (case) | Type 2 diabetes | Try 3 of 4 listed drugs first | Upheld | Of the listed alternatives, only Ozempic was tried (stopped for nausea). Type 2 diabetes was documented, but A1C was 6.0% on metformin and records didn't show why more glucose lowering was needed |
| 2024 | MassHealth, state Medicaid (decision, July 3) | Type 2 diabetes | Trials of cheaper drugs first | Appeal denied | He reported metformin intolerance, but required trial details weren't documented; he didn't want to try the alternatives. The doctor could submit a new PA with records |
| 2023 | Aetna EPO (case) | Obesity | Listed GLP-1 drugs | Overturned | Only 4 pounds lost on Ozempic; heart history; reviewer favored a drug that works differently |
| 2023 | Aetna PPO (case) | Obesity | Not on the drug list | Overturned | 37 pounds lost on Ozempic, then no change for 5+ months |
| 2023 | Aetna PPO (case) | Obesity | Try Ozempic and Rybelsus | Overturned | Records showed both had been tried and failed |
| 2022 | Oscar EPO (case) | Obesity and prediabetes | Medical necessity | Overturned | Saxenda, Ozempic, and top-dose Wegovy had all failed |
| 2022 | Healthfirst, NY Medicaid (case) | Obesity | Listed drugs first | Upheld | Wegovy had failed, but Ozempic, Trulicity, and Victoza had not been tried and no reason they were unsafe was shown; reviewer also noted no obesity indication |
Three lessons from these cases:
- Write down every drug you tried, with dates and what happened. Also ask your prescriber to explain why any remaining required options don't fit. Trial records mattered, but they weren't the only issue.
- "I don't want to try it" wasn't enough in the Massachusetts case. The reviewer needed records supporting a medical reason for an exception.
- Stability mattered in two diabetes cases. Those reviewers considered both the patient's response to Mounjaro and why other options were a poor fit.
These 10 cases aren't a success rate, and they don't predict your outcome. Each was decided on one person's records, under the rules and drug options at that time: New York in 2022–2023, Massachusetts in July 2024. None had the August 2026 heart-risk label to point to. They show what those reviewers considered, not what your plan must approve today. For more on this step, see our guide to external review for GLP-1 denials.
What if you have Medicare or Medicaid?
Medicare drug plans can cover diabetes medicines like Mounjaro under their own rules, and their appeals start with a "redetermination" generally requested within 65 days of the notice date. Part D law excludes drugs used only for weight loss; the separate Bridge program below operates outside the usual Part D benefit. Medicaid health plans give you 60 days to appeal, then a state fair hearing.
Medicare drug plans (Part D and Medicare Advantage)
Medicare has five appeal levels after the first coverage decision.
| Step | What it is | Your deadline | Decision time / other requirement |
|---|---|---|---|
| Coverage determination or exception | Your first request, or asking for an exception to the drug list or a rule | Request coverage or an exception before the appeal stage | For a benefit request: 72 hours; 24 if urgent (exceptions: counted from your prescriber's statement) |
| 1. Redetermination | Your plan reviews its own denial | Generally 65 days from the date on the notice | Benefit appeal: 7 days; 72 hours if urgent. Payment appeal: 14 days |
| 2. Independent Review Entity | An outside reviewer looks at it | Generally 65 days from the date on the plan's appeal decision (CMS) | Benefit appeal: 7 days; 72 hours if urgent. Payment appeal: 14 days |
| 3. Judge hearing | Administrative law judge | Ordinarily 60 days after you receive the IRE decision | At least $200 must be in dispute (2026) |
| 4–5. Appeals Council, then federal court | Final levels | Ordinarily 60 days after you receive the preceding decision at each step; follow any special expedited instructions | Federal court needs $1,960 in dispute in 2026 |
Sources: Medicare.gov drug plan appeals, 2026 amounts in dispute. The 65-day summaries use the five-day receipt assumption explained above. The IRE can extend its decision period by up to 14 days in certain cases; it must tell you why. Later appeal steps have their own receipt and expedited rules (42 CFR 423.600, 423.2002, 423.2102, 423.2130).
An exception needs a supporting statement from your prescriber saying the plan's preferred drugs would be less effective, would cause harm, or already didn't work (CMS exceptions).
Two things Medicare members ask about:
- The Lilly savings card doesn't work with Medicare, including Part D and Medicare Advantage (Lilly terms). Here's why Medicare patients can't use GLP-1 savings cards.
- The Medicare GLP-1 Bridge doesn't cover Mounjaro. It offers Wegovy injections or tablets, Zepbound KwikPen, and Foundayo for $50 a month to eligible people from July 1, 2026 to December 31, 2027. People with type 2 diabetes aren't eligible (CMS eligibility rules, Medicare.gov fact sheet). If you have type 2 diabetes, your regular drug plan and its appeals are your path. More on Medicare Advantage and Mounjaro.
Medicaid
If a Medicaid health plan denied Mounjaro, you have 60 days from the date on the notice to appeal to the plan. It must decide within the state's limit of no more than 30 days, or 72 hours if urgent, with extensions allowed in certain cases. If it says no again, you can ask for a state fair hearing; your state gives you between 90 and 120 days from the plan's appeal-resolution notice to request it (42 CFR 438.402 and 438.408).
Medicaid must respond to drug prior authorization requests within 24 hours (Social Security Act §1927(d)(5)). That response is not a promise of approval, and it isn't the appeal decision clock.
Already approved and being cut off early? If the plan is stopping or reducing an approval that hasn't expired yet, you may be able to keep your benefits during the appeal. You must request continued benefits as well as appeal. For qualifying services already approved and ordered by an authorized provider, ask within 10 calendar days after the plan sends the notice, or by the date the change takes effect, whichever is later. The original approval period must not have expired.
To keep those benefits after the plan denies your appeal, request both a state fair hearing and continued benefits within 10 calendar days after the plan sends its appeal-denial notice. The longer 90–120-day hearing window does not preserve continued benefits.
If the final outcome upholds the denial, the plan may recover the cost of continued benefits under applicable state and contract rules (42 CFR 438.420). Ask the plan about the repayment risk before you decide.
If your Medicaid is run directly by your state rather than a health plan, follow the steps and dates in your state's notice. See does Medicaid cover Mounjaro for coverage by state.
What can you do while you wait?
Keep your treatment plan and your appeal moving at the same time. If you meet Lilly's savings-card rules, it can lower your cost even while your private plan says no, through December 31, 2026. Don't stop, stretch, or change your dose without talking to your prescriber.
| Your situation | What Lilly lists | The fine print |
|---|---|---|
| Eligible private insurance that covers Mounjaro | Savings card: as little as $25 for a 1-, 2-, or 3-month fill of single-dose pens | Savings caps: $150 / $300 / $450 per 1- / 2- / 3-month fill; $1,950 a year |
| Eligible private insurance that doesn't cover Mounjaro | Savings card: as low as $499 for a 1-month (28-day, 4-pen) fill | Savings cap: $647 per fill; $8,411 a year; up to 13 fills |
| Medicare, Medicaid, TRICARE, VA, or another government plan | Not eligible for the savings card | See the Medicare and Medicaid section |
| Paying yourself through LillyDirect | Single-dose pens starting at $499 per 28 days (4 pens), listed for each strength | Age 18+; prescription for an approved use; taxes or fees may add to the price. Cannot submit this purchase for insurance reimbursement or count it toward a deductible or out-of-pocket limit |
Sources: Mounjaro savings terms, LillyDirect Mounjaro, and LillyDirect purchase terms; checked October 21, 2026.
The card has rules worth knowing. You must be 18 or older, live in the U.S. or Puerto Rico, have eligible commercial insurance, and activate the card. The medicine must be prescribed for a use on its FDA label. That means type 2 diabetes. Government coverage and plans that require certain outside funding programs don't qualify.
The offer covers single-dose pens: 1 month is 28 days and 4 pens; 2 months is 56 days and 8 pens; 3 months is 84 days and 12 pens. Savings are limited to 13 fills a year. You owe charges above the cap, plus applicable taxes or fees, and cannot claim reimbursement for the card-funded amount. The card ends December 31, 2026, and Lilly can change the terms anytime. More details are in our Mounjaro savings card guide and Mounjaro cost without insurance.
If paying $499 while you wait isn't possible, tell your prescriber. They decide what's safe for you in the meantime, and they can ask the plan for an urgent review if a gap would put your health at risk.
What if your Mounjaro appeal is denied again?
Read the new denial for the reason and the next step it lists. A job-based plan may require a second internal appeal. An ACA-protected individual plan, including Marketplace coverage, has one internal appeal before its final determination. After required internal appeals, an eligible denial can go to outside review. The federal process gives you 4 months; confirm which federal or state process applies. Medicare goes to an Independent Review Entity after a plan redetermination, and Medicaid health plans go to a state fair hearing after the plan appeal.
Start by finding the gap. Which part of the rule does your packet still not answer? Fill that gap with real records. Don't add claims you can't support to make the packet sound stronger.
| Your coverage | Next step | How to start |
|---|---|---|
| Job-based or Marketplace, after required internal appeals | Eligible external review: free under the HHS federal process; qualifying state processes may charge up to $25. Federal decision clock: 45 days, or 72 hours if urgent | Follow your final denial notice; see HealthCare.gov external review |
| Self-funded job plan | Usually the federal external review process; your plan administrator handles the request | Ask HR or the plan administrator; see Department of Labor guidance |
| Medicare drug plan | Independent Review Entity | Use the form and address in your plan's decision (CMS) |
| Medicaid health plan | State fair hearing | Use the instructions in the plan's appeal decision |
External review only covers some denials, mostly ones about medical judgment, like "not medically necessary." A pure contract exclusion may not qualify. Your final notice should say whether it does. Our page on GLP-1 appeal levels walks through each level.
If you've used every level and the answer is still no, your options come down to a medicine your plan covers, a different plan at open enrollment, or paying yourself. Your prescriber is the right person for the first. To compare other GLP-1 paths and providers that fit your goals, budget, insurance, and situation, use Find My GLP-1 Path.
Find the GLP-1 path that fits you now
What we actually verified
We read the current FDA labels, five published plan rules, the federal appeal rules listed below, Lilly's savings and self-pay pages and terms, Ro's pages, and 10 public appeal decisions. We didn't see your plan's contract, your records, or your notice. Check those documents for the rule applied to your case, and question any conflict with the appeal rights described here.
Last verified October 21, 2026.
| What we checked | Where | Checked |
|---|---|---|
| Mounjaro and Zepbound approved uses | Lilly prescribing information, both revised August 2026 | Oct 21, 2026 |
| Appeal deadlines and decision times | eCFR (29 CFR 2560.503-1; 45 CFR 147.136 and 156.122; 42 CFR 423 and 438), HealthCare.gov, Department of Labor, CMS, Medicare.gov | Oct 21, 2026 |
| Plan rules | UnitedHealthcare (eff. July 1, 2026), Cigna IP0701 for selected employer-plan drug lists (eff. June 15, 2026), CVS Caremark default (P05-2025), Aetna published UDR 05-2024 bulletin, FEP Blue (eff. July 1, 2026) | Oct 21, 2026 |
| Medicare GLP-1 Bridge | CMS overview (updated July 13, 2026), provider eligibility page (updated August 6, 2026), Medicare.gov fact sheet | Oct 21, 2026 |
| Savings card and self-pay prices | Lilly's savings-card terms, LillyDirect price listings and purchase terms | Oct 21, 2026 |
| Ro's offerings and prices | Ro's pricing, insurance FAQ, and page stating it does not offer Mounjaro | Oct 21, 2026 |
| Appeal decisions | New York DFS external appeal database (2022–2023); Massachusetts Board of Hearings (July 3, 2024) | Oct 21, 2026 |
Prices are what Lilly and Ro list on their own pages; we didn't complete a checkout. "Verified" means we checked it against the public source named. It doesn't mean you qualify or that a plan will pay.
You can read our methodology, or start with the general GLP-1 appeal process if your denial is for a different drug.
Frequently asked questions
Why was Mounjaro denied if it keeps my A1C under control?
The plan may only have seen your current A1C, not the records from when you were diagnosed. Ask your prescriber to send both the original diagnosis and your current results, matched to the rule in your notice. Some plans, like UnitedHealthcare and FEP Blue, have renewal paths that look for exactly that.
Can I appeal myself if my doctor's office says it can't appeal further?
Often, yes. Most plans let the member file an appeal, but which step is still open depends on your plan and where you are in the process. Get the written decision and ask the plan which member appeal you can file. The medical evidence still has to come from your records or your prescriber.
Do I have to try metformin before Mounjaro?
It depends on your plan. The UnitedHealthcare, Cigna IP0701, and CVS Caremark documents above don't list a metformin-first rule. Aetna's published UDR 05-2024 bulletin requires an inadequate response to metformin, intolerance, or a reason it is unsafe—or combination therapy with A1C of at least 7.5%. Ask which rule your plan used. If you've taken metformin before or can't take it, have your prescriber document that.
What A1C do I need for Mounjaro to be approved?
The public rules above look for proof of type 2 diabetes; several accept a recorded A1C of 6.5% or higher, now or at diagnosis. The cited Aetna May 2024 bulletin has a separate combination-therapy pathway requiring an A1C of at least 7.5%. Ask your plan for the written rule used in your denial.
Can I use the Mounjaro savings card if insurance denied it?
If you're 18 or older, have eligible commercial insurance, and Mounjaro is prescribed for an approved type 2 diabetes use, Lilly lists as low as $499 for a 28-day, 4-pen fill when your plan doesn't cover it. Other card rules and savings caps still apply. The card ends December 31, 2026. People on Medicare, Medicaid, or other government plans can't use it.
Does prediabetes count for Mounjaro coverage?
Mounjaro's label covers type 2 diabetes, not prediabetes. The five public plan rules above ask for proof of type 2 diabetes. A request for prediabetes alone is for an off-label use; check the notice for the exact denial reason. See our guide on Mounjaro coverage for prediabetes.
Does a peer-to-peer call count as my appeal?
Don't assume it does. A peer-to-peer is a call between your doctor and the plan's reviewer. Ask the plan whether it's part of a formal appeal, who filed that appeal, and whether your deadline changed, and get the answer in writing.
Do I have to pay someone to appeal?
No. You can write and file the patient letter yourself for free. ERISA job-based plans can't charge to file an appeal, and the HHS federal external review process is free; qualifying state external reviews may cost up to $25. Your doctor's office may charge for records or forms, so ask.
Can I keep getting Mounjaro while the appeal is pending?
Not automatically. Ask the plan whether any temporary coverage applies, and ask your prescriber for a plan in the meantime. On Medicaid, if an approval is being cut off before it expires, you may keep benefits during the appeal if you qualify and meet the continued-benefit request deadlines, but you could owe the cost if the final decision is against you.
What if I missed the deadline?
Call the plan right away and ask whether you can still file late. Medicare drug plans let you ask for more time for a good reason, with a written explanation. That's a request the plan can deny, not a guarantee.
How long does a Mounjaro appeal take?
ERISA job-based and ACA-protected individual plans generally have up to 30 days for a pre-service appeal, with 15 days per level when a job plan requires two levels. Medicare drug-plan benefit appeals have 7 days; payment appeals have 14. Urgent benefit appeals have a 72-hour clock. Federal external review can add up to 45 days. See the table above for the separate drug-exception and Medicaid rules.
Should I ask my doctor for Zepbound instead?
If you don't have type 2 diabetes and the goal is weight, Zepbound is the tirzepatide product approved for that. Your clinician decides whether it's right for you. It's a new prescription with its own approval, and plans that exclude weight-loss drugs may deny it too.
Still not sure which GLP-1 path fits you? Take The RX Index's free Find My GLP-1 Path quiz — about 2 minutes, no signup.
Sources
All checked October 21, 2026. Source dates and offer deadlines are labeled separately.
- Mounjaro prescribing information (revised 08/2026)
- Zepbound prescribing information (revised 08/2026)
- FDA: Zepbound approval for chronic weight management (November 8, 2023)
- NIDDK: The A1C test and diabetes
- 29 CFR 2560.503-1, ERISA claims procedure
- U.S. Department of Labor: Filing a claim for your health benefits
- 45 CFR 147.136, internal appeals and external review
- OPM: Federal holidays (calendar used for the federal external-review helper)
- 45 CFR 156.122, drug exceptions process
- HealthCare.gov: Internal appeals
- HealthCare.gov: External review
- CMS: Redetermination by the Part D plan
- CMS: Part D exceptions
- CMS: Part D reconsideration by the Independent Review Entity
- 42 CFR 423.582, Part D redetermination requests
- 42 CFR 423.600, IRE reconsiderations
- 42 CFR 423.2002, judge-hearing requests, 423.2102, Appeals Council requests, and 423.2130, judicial review
- Social Security Act §1860D-2, Part D covered-drug rules
- Medicare.gov: Drug plan appeals
- Federal Register: 2026 amounts in controversy (Dec 4, 2025)
- CMS: Medicare GLP-1 Bridge (updated 07/13/2026)
- CMS: Medicare GLP-1 Bridge provider eligibility rules (updated 08/06/2026)
- Medicare.gov: Medicare GLP-1 Bridge fact sheet
- 42 CFR Part 438 Subpart F, Medicaid managed care appeals
- 42 CFR 438.420, continuation of benefits
- Social Security Act §1927, Medicaid drug prior authorization
- UnitedHealthcare commercial GLP-1 criteria (effective 07/01/2026)
- Cigna employer-plan GLP-1 policy IP0701, selected drug lists (effective 06/15/2026)
- CVS Caremark default GLP-1 criteria 5694-D (P05-2025) and quantity limits 4525-H
- Aetna Mounjaro policy 5468-C (05-2024)
- FEP Blue policy 5.30.086 (effective 07/01/2026)
- Mounjaro savings terms (offer ends 12/31/2026)
- LillyDirect: Mounjaro and purchase terms
- Lilly sample letter of medical necessity
- Ro weight-loss pricing, Ro insurance, and Ro's statement that it does not offer Mounjaro
- New York DFS external appeal decisions: 202305-163384, 202305-162722, 202301-158173, 202305-162460, 202304-161488, 202304-162002, 202305-162818, 202211-155151, 202210-155007
- Massachusetts Board of Hearings, Appeal 2405606 (July 3, 2024)